Skip to content
Bomb Report – Lifestyle
Author:
BELL TECHLOGIX
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure
August 18, 2026
Bell Techlogix Earns 2026 Great Place To Work Certification™ – for Fourth Consecutive Year
June 23, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
April 8, 2026
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer’s Disease
April 7, 2026
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
March 30, 2026
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
March 19, 2026
IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026
March 18, 2026
Bell Techlogix Announces 2026 Racing Season Partnership with Pippa Mann
March 16, 2026